scholarly journals The role of neoadjuvant therapy in pancreatic cancer: a review

2016 ◽  
Vol 12 (5) ◽  
pp. 669-685 ◽  
Author(s):  
Suzanne Russo ◽  
John Ammori ◽  
Jennifer Eads ◽  
Jennifer Dorth
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy

scholarly journals The Role of Neoadjuvant Therapy in Surgical Treatment of Pancreatic Cancer

2018 ◽  
Author(s):  
Laura Antolino ◽  
Paolo Aurello ◽  
Federico Todde ◽  
Silvia Amato ◽  
Niccolò Petrucciani ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Surgical Treatment ◽  
Neoadjuvant Therapy

scholarly journals The Role of MRI Pancreatic Protocol in Assessing Response to Neoadjuvant Therapy for Patients With Borderline Resectable Pancreatic Cancer

2022 ◽  
Vol 11 ◽  
Author(s):  
Nervana Hussien ◽  
Rasha S. Hussien ◽  
Darine Helmy Amin Saad ◽  
Mohamed El Kassas ◽  
Walid F. Elkhatib ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Operative Procedure ◽  
Resectable Pancreatic Cancer ◽  
Borderline Resectable ◽  
Borderline Resectable Pancreatic Cancer ◽  
Number Of Patients ◽  
Magnetic Resonance Imaging Mri ◽  
Post Therapy

BackgroundBorderline Resectable Pancreatic Cancer (BRPC) remains a unique entity that is difficult to categorize due to variance in definitions and the small number of patients. The ultimate goal is to achieve a free resection (R0) after a favorable response to neoadjuvant therapy that is somewhat difficult to assess by current radiological parameters.AimTo evaluate the role of Magnetic Resonance Imaging (MRI) pancreatic protocol, including Diffusion-Weighted Imaging (DWI), in patients with BRPC receiving neoadjuvant therapy, and further compare it to RECIST criteria and outcome.MethodsHistologically confirmed BRPC patients were prospectively included. DWI-MRI was performed pre- and post-therapy. Clinical characteristics with ensuing operability were recorded and correlated to radiological RECIST/apparent diffusion coefficient (ADC) change, preoperative therapy administrated, surgical resection status, and survival.ResultsOut of 30 BRPC cases, only 11 (36.7%) ultimately underwent pancreaticoduodenectomy. Attaining a stationary or stable disease via ADC/RECIST was achieved in the majority of cases (60%/53.3% respectively). Of the 12 patients (40%) who achieved a regression by ADC, 11 underwent surgery with an R0 status. These surgical cases showed variable RECIST responses (PR=5, SD=4, PD=3). Responders by ADC to neoadjuvant therapy were significantly associated to presenting with abdominal pain (p =0.07), a decline in post-therapy CA19-9 (p<0.001), going through surgery (p<0.001), and even achieving better survival (p<0.001 vs. 0.66).ConclusionDWI-MRI ADC picked up patients most likely to undergo a successful operative procedure better than traditional RECIST criteria. An algorithm incorporating novel radiological advances with CA19-9 deserves further assessment in future studies.

Role of Neoadjuvant Therapy in the Multimodality Treatment of Older Patients with Pancreatic Cancer

2014 ◽  
Vol 219 (1) ◽  
pp. 111-120 ◽  
Author(s):  
Amanda B. Cooper ◽  
Holly M. Holmes ◽  
Jude K.A. des Bordes ◽  
David Fogelman ◽  
Nathan H. Parker ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Older Patients ◽  
Multimodality Treatment

scholarly journals Role of neoadjuvant therapy and adjuvant therapy in treatment of pancreatic cancer

2013 ◽  
Vol 21 (14) ◽  
pp. 1292
Author(s):  
Peng Huang ◽  
Xiang-Yu Zhong ◽  
Yi Xu ◽  
Yun-Fu Cui
Keyword(s):  
Pancreatic Cancer ◽  
Adjuvant Therapy ◽  
Neoadjuvant Therapy

Role of Molecular Profiling of Pancreatic Cancer After Neoadjuvant Therapy: Does it Change Practice?

2019 ◽  
Vol 24 (2) ◽  
pp. 235-242
Author(s):  
Ashley N. Krepline ◽  
Lindsay Bliss ◽  
Jennifer Geurts ◽  
Idayat Akinola ◽  
Kathleen K. Christians ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Neoadjuvant Therapy ◽  
Molecular Profiling
Sign in / Sign up

Export Citation Format

Share Document